3 Dividend Stocks to Double Up on Right Now

In This Article:

It's no secret that inflation has caused prices of goods and services to rise in the last few years. The need to spend more just to maintain your current standard of living is a constant worry for many families.

There is an attractive solution to this problem: buying dividend stocks that can supply you with a stream of additional passive income to supplement your earned income. The ideal dividend stock should be a business with a strong competitive edge that possesses a long track record of increasing dividends. It should also generate huge amounts of free cash flow that can sustain its dividend payments.

Such dividend stock candidates should sit well within your portfolio to supply you with the dividends you need to not only beat inflation but also provide you with some extra spending money for the nicer things in life. Here are three attractive dividend stocks that you can consider adding to your income portfolio.

Worker welding oil pipeline.
Image source: Getty images.

1. Medtronic

Medtronic (NYSE: MDT) makes medical devices for a wide range of specialities such as cardiovascular, diabetes, respiratory, spinal, and neurological. The company has a stellar track record of increasing its dividend over 47 consecutive years, with its latest being a quarterly dividend of $0.70 per share.

Net sales went from $31.7 billion in fiscal 2022 (ended April 30) to $32.4 billion in 2024. Net income, however, fell from $5 billion to $3.7 billion over the same period because of higher costs of goods sold and interest expenses.

Despite the lower profit, Medtronic continued to generate consistent free cash flow, which averaged around $5.3 billion per fiscal year. With a payment of $3.67 billion in dividends for fiscal 2024, the dividend amounted to 70% of Medtronic's free cash flow and is, therefore, sustainable.

The company reported earnings for the first half of fiscal 2025 as inflation starts to abate. Revenue rose 4% year over year to $16.3 billion, while operating income climbed 10.2% to $2.9 billion. With Medtronic enjoying a lower tax expense for the period, net income surged by 36% to $2.3 billion. Free cash flow for the business jumped 41% to $1 billion, building confidence that Medtronic can continue with its impressive track record of increasing dividends.

The company continued its innovative streak, with close to 120 product approvals in the past 12 months, adding to its burgeoning portfolio of products and devices that cover a wide range of specialities and geographies. Interim CFO Gary Corona mentioned that Medtronic is focused on improving its margins and is increasing productivity through the centralization of operations and the consolidation of factories and suppliers. He also mentioned several promising new product launches that have yet to meaningfully scale up and deliver their full potential.